PREVENTION OF IRON LOADING IN TRANSFUSION-DEPENDENT THALASSÆMIA
- 1 June 1978
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 311 (8075), 1178-1181
- https://doi.org/10.1016/s0140-6736(78)90968-6
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Intensive Iron-Chelation Therapy with Desferrioxamine in Iron-Loading AnaemiasClinical Science, 1978
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977
- EFFECT OF DOSE, TIME, AND ASCORBATE ON IRON EXCRETION AFTER SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1977
- SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOADThe Lancet, 1976
- LONG‐TERM DESFERRIOXAMINE THERAPY IN THALASSEMIAAnnals of the New York Academy of Sciences, 1974
- Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical ProgressBMJ, 1974
- The Effect of Ascorbic Acid Deficiency on Desferrioxamine‐Induced Urinary Iron ExcretionBritish Journal of Haematology, 1969
- Clinical and Laboratory Studies on the Action of DesferrioxamineBritish Journal of Haematology, 1969
- Deferoxamine mesylate (Desferal mesylate); A specific iron‐chelating agent for treating acute iron intoxicationClinical Pharmacology & Therapeutics, 1969
- Application of Atomic Absorption Spectrophotometry in the Determination of Iron in UrineAmerican Journal of Clinical Pathology, 1965